Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NETWORK 6NIH 5OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 8Sarcoma 5Neoplasms 4Lymphoma, Non-Hodgkin 4Immunoproliferative Disorders 3Recurrence 2Osteosarcoma 2Neoplasm Metastasis 2Lymphoproliferative Disorders 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Lymphoma 2Lymphatic Diseases 2Hematologic Diseases 2Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms by Histologic Type 1Liposarcoma 1Leiomyosarcoma 1Immune System Diseases 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Fibrosarcoma 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Renal Cell 1Bone Neoplasms 1B-Cell Malignancies 1

Interventions

Trabectedin 4Doxorubicin 4toripalimab 2brigimadlin 2belinostat 2Fulvestrant 2Dexamethasone 2tanespimycin 1soblidotin 1siremadlin 1selinexor 1ridaforolimus 1ribociclib 1pembrolizumab 1olaratumab 1milademetan 1enzalutamide 1cemiplimab 1atezolizumab 1TTI-621 1Sugars 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Midazolam 1Letrozole 1Injections 1Immunotherapy 1Imatinib Mesylate 1Ifosfamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Liposarcoma × Ifosfamide × Clear all
NCT06277154 2025-07-24

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

HRYZ Biotech Co.

Phase 2 Recruiting
148 enrolled
GynecologicSarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Endometrial Stromal, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡